Medplus Health Services Subsidiary Faces Drug License Suspension in Telangana, Potential Revenue Loss Noted
Medplus Health Services Limited has reported that Optival Health Solutions Private Limited, a subsidiary of the company, received an order suspending its Drug License for a store located in Telangana. The suspension pertains to a specific operational location and is attributed to alleged contraventions under Indian drug control legislation.The suspension was issued by the Assistant Director, Drugs Control Administration, Warangal, Telangana, following the receipt of the direction or order on July 30, 2026. The action involves the temporary halt of operations at a store situated in SBH Colony Hanamkonda.
The licensing action is based on alleged violations under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.
Key details regarding the suspension and its implications are presented below:
| Authority | Action Taken | Date of Order Receipt | Violation Details | Financial Impact |
|---|---|---|---|---|
| Assistant Director, Drugs Control Administration, Warangal, Telangana | Suspension of Drug License for five days at the SBH Colony Hanamkonda store. | 30.07.2026 | Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. | Potential Revenue Loss of Rs 2.34 lacs. |
The incident highlights the regulatory compliance challenges faced by Medplus Health Services Limited’s subsidiary in relation to its drug licensing portfolio. The suspension order specifically targets a five-day operational period for the store in Hanamkonda, Telangana, and indicates a quantified potential revenue loss of Rs 2.34 lacs.
MEDPLUS Stock Price Movement
Shares of Medplus Health Services Limited slipped today, settling at ₹704.95 after the stock shed 1.39% in post-market trading. The equity traded between a day low of ₹699 and a high of ₹724, with a reported volume of 218,452 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.